Mesoblast (MESO) Cash from Financing Activities (2016 - 2023)
Mesoblast (MESO) posted quarterly Cash from Financing Activities of $38.8 million for Q2 2023, up 1848.96% year-on-year from $2.0 million in Q2 2022, and up 1625.27% on a QoQ basis from -$2.5 million in Q1 2023.
Mesoblast (MESO) Cash from Financing Activities (2016 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Cash from Financing Activities for 8 consecutive years, with $38.8 million the latest figure, recorded in Q2 2023.
- Quarterly Cash from Financing Activities rose 1848.96% year-over-year to $38.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $74.5 million (up 854.83% YoY) and the FY2025 annual result came in at $147.3 million, up 266.03% from the prior year.
- Cash from Financing Activities improved to $38.8 million in Q2 2023 per MESO's latest filing, from -$2.5 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for MESO reached as high as $106.4 million in Q1 2021 and fell as low as -$2.9 million in Q4 2021.
- A 5-year average of $17.8 million and a median of -$50500.0 in 2019 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2020 — Cash from Financing Activities soared 251518.18% — and 2021, when it tumbled 294.22%.
- Year by year, Cash from Financing Activities stood at $48.2 million in 2019, then slumped by 101.54% to -$744000.0 in 2020, then slumped by 294.22% to -$2.9 million in 2021, then jumped by 31.4% to -$2.0 million in 2022, then soared by 2026.29% to $38.8 million in 2023.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $38.8 million, -$2.5 million, and -$2.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 38.76 Mn |
| Jun 30, 2023 | 38.76 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Sep 30, 2021 | -2.15 Mn |
| Sep 30, 2021 | -2.15 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Mar 31, 2021 | 106.36 Mn |
| Mar 31, 2021 | 106.36 Mn |